KAPA Kairos Pharma, Ltd.
Fundamentals / CIK 0001962011 / USDKairos Pharma, Ltd. reported $4.37M in total assets and a net loss of $6.39M through December 31, 2025 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open KAPA in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025-- Dec 31, 2025
-
Operating Income FY 2025-$6.53M Operating profit
-
Net Income FY 2025-$6.39M GAAP bottom line
-
Diluted EPS FY 2025-$1.91 Split-adjusted
-
Free Cash Flow FY 2025-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$3.12M Total debt: --
Annual revenue and net income
3 fiscal years (2023 to 2025), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Research & Development | $2.13M | $414K | $82K |
| Total Operating Expenses | $5.57M | $2.34M | $1.71M |
| Operating Income | -$5.57M | -$2.34M | -$1.71M |
| Interest Expense | -- | $35K | $42K |
| Net Income | -$5.45M | -$2.60M | -$1.81M |
| Basic EPS | -$2.10 | -$1.61 | -$1.19 |
| Diluted EPS | -$2.10 | -$1.61 | -$1.19 |
| Basic Shares Outstanding | 2.6M | 1.6M | 1.5M |
| Diluted Shares Outstanding | 2.6M | 1.6M | 1.5M |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Research & Development | $892K | $619K | $684K | $538K | $608K | $496K | $493K | $172K |
| Total Operating Expenses | $2.01M | $1.42M | $1.69M | $1.42M | $1.44M | $1.46M | $1.27M | $1.45M |
| Operating Income | -$2.01M | -$1.42M | -$1.69M | -$1.42M | -$1.44M | -$1.46M | -$1.27M | -$1.45M |
| Interest Expense | -- | -- | -- | -- | -- | -- | -- | $0 |
| Net Income | -$1.98M | -$1.39M | -$1.65M | -$1.36M | -$1.40M | -$1.42M | -$1.26M | -$980K |
| Basic EPS | -$0.59 | -$0.42 | -$0.56 | -- | -$0.48 | -$0.56 | -$0.56 | -- |
| Diluted EPS | -$0.59 | -$0.42 | -$0.56 | -- | -$0.48 | -$0.56 | -$0.56 | -- |
| Basic Shares Outstanding | 3.3M | 3.1M | 3.0M | -- | 2.9M | 2.5M | 2.3M | -- |
| Diluted Shares Outstanding | 3.3M | 3.1M | 3.0M | -- | 2.9M | 2.5M | 2.3M | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & Cash Equivalents | $4.49M | $1.27M | $93K |
| Cash & Short-Term Investments | $4.49M | $1.27M | $93K |
| Total Current Assets | $5.39M | $4.17M | $101K |
| Intangible Assets | $62K | $222K | $382K |
| Total Non-Current Assets | $1.15M | $1.60M | $864K |
| Total Assets | $6.54M | $5.77M | $965K |
| Total Current Liabilities | $199K | $992K | $2.40M |
| Total Non-Current Liabilities | $0 | $0 | $638K |
| Total Liabilities | $199K | $992K | $3.04M |
| Common Stock | $3.0K | $14K | $11K |
| Retained Earnings | -$14.26M | -$8.81M | -$6.21M |
| Total Stockholders' Equity | $6.34M | $4.78M | -$2.08M |
| Total Equity | $6.34M | $4.78M | -$2.08M |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $3.12M | $2.63M | $3.67M | $4.49M | $5.58M | $3.03M | $3.62M | $1.27M |
| Cash & Short-Term Investments | $3.12M | $2.63M | $3.67M | $4.49M | $5.58M | $3.03M | $3.62M | $1.27M |
| Total Current Assets | $3.35M | $3.17M | $4.44M | $5.39M | $6.66M | $4.84M | $6.05M | $4.17M |
| Intangible Assets | -- | $191K | $22K | $62K | $102K | $142K | $182K | $222K |
| Total Non-Current Assets | $1.02M | $1.28M | $1.30M | $1.15M | $1.41M | $1.83M | $1.89M | $1.60M |
| Total Assets | $4.37M | $4.46M | $5.74M | $6.54M | $8.07M | $6.67M | $7.94M | $5.77M |
| Total Current Liabilities | $495K | $265K | $431K | $199K | $402K | $676K | $805K | $992K |
| Total Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $495K | $265K | $431K | $199K | $402K | $676K | $805K | $992K |
| Common Stock | $4.0K | $21K | $21K | $3.0K | $21K | $18K | $16K | $14K |
| Retained Earnings | -$19.29M | -$17.30M | -$15.92M | -$14.26M | -$12.90M | -$11.50M | -$10.08M | -$8.81M |
| Total Stockholders' Equity | $3.88M | $4.19M | $5.31M | $6.34M | $7.66M | $6.00M | $7.13M | $4.78M |
| Total Equity | $3.88M | $4.19M | $5.31M | $6.34M | $7.66M | $6.00M | $7.13M | $4.78M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Net Income | -$5.45M | -$2.60M | -$1.81M |
| Operating Cash Flow | -$3.44M | -$3.96M | $81K |
| Financing Cash Flow | $6.66M | $5.13M | -$425K |
| Net Change in Cash | $3.22M | $1.18M | -$344K |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$1.98M | -$1.39M | -$1.65M | -$1.36M | -$1.40M | -$1.42M | -$1.26M | -$980K |
| Operating Cash Flow | -$979K | -$1.01M | -$1.04M | -$1.08M | -$838K | -$805K | -$714K | -$1.80M |
| Financing Cash Flow | $1.48M | -$37K | $220K | $0 | $3.38M | $223K | $3.06M | -$142K |
| Net Change in Cash | $499K | -$1.05M | -$816K | -$1.08M | $2.54M | -$582K | $2.34M | -$1.95M |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Return on Equity (ROE) | -85.9% | -54.5% | -- |
| Return on Assets (ROA) | -83.3% | -45.1% | -187.8% |
| Current Ratio | 27.07x | 4.20x | 0.04x |
| Quick Ratio | 22.57x | 1.28x | 0.04x |
| Operating Cash Flow Growth (YoY) | -- | -4982.7% | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -164.9% | -138.5% | -109.9% | -85.9% | -66.0% | -78.6% | -49.7% | -54.5% |
| Return on Assets (ROA) | -146.2% | -130.3% | -101.7% | -83.3% | -62.8% | -70.6% | -44.6% | -45.1% |
| Current Ratio | 6.77x | 11.98x | 10.31x | 27.07x | 16.56x | 7.16x | 7.52x | 4.20x |
| Quick Ratio | 6.31x | 9.91x | 8.53x | 22.57x | 13.87x | 4.49x | 4.49x | 1.28x |
| Operating Cash Flow Growth (YoY) | -- | -- | -- | -- | -- | -- | -2083.3% | -- |